Published in Cancer Res on February 08, 2011
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics (2013) 1.30
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene (2011) 1.30
Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res (2014) 1.09
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood (2011) 1.02
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer (2011) 0.99
Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics (2013) 0.98
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res (2016) 0.91
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest (2015) 0.90
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget (2012) 0.89
Developmental Stage-Specific Hepatocytes Induce Maturation of HepG2 Cells by Rebuilding the Regulatory Circuit. Mol Med (2015) 0.78
Does Wnt/β-catenin pathway contribute to the stability of DNMT1 expression in urological cancer cell lines? Exp Biol Med (Maywood) (2014) 0.76
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PLoS One (2016) 0.75
Pitfalls in experimental designs for characterizing the transcriptional, methylational and copy number changes of oncogenes and tumor suppressor genes. PLoS One (2013) 0.75
DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. Cell Death Dis (2017) 0.75
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer (1983) 11.19
An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) (1995) 9.18
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell (1996) 7.69
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet (2003) 3.91
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res (1999) 3.29
Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood (2002) 3.21
Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med (2000) 3.15
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood (1994) 2.51
Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol (2002) 2.17
Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res (2007) 2.04
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther (1995) 1.62
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res (1990) 1.53
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res (2006) 1.26
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol (1987) 1.14
Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol (2009) 1.11
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res (1986) 1.11
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer (2005) 1.11
Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther (2010) 1.05
The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Clin Cancer Res (2004) 1.00
Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther (2008) 0.99
Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol (2008) 0.99
Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma (1968) 0.96
5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells. Am J Hematol (2004) 0.94
WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene (1999) 0.92
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res (2003) 0.88
Epigenetic therapies move into new territory, but how exactly do they work? J Natl Cancer Inst (2009) 0.87
Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer (2001) 0.81
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res (2004) 0.80
5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br J Pharmacol (2008) 0.79
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol (2009) 0.77
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood (2008) 2.87
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood (2012) 2.50
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res (2013) 2.00
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
EVI1 induces myelodysplastic syndrome in mice. J Clin Invest (2004) 1.72
Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc (2010) 1.63
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res (2007) 1.52
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res (2004) 1.43
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma (2014) 1.41
PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration. J Cell Biol (2003) 1.37
Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci U S A (2005) 1.32
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med (2002) 1.25
Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J Biol Chem (2004) 1.23
Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J Biol Chem (2005) 1.22
p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2003) 1.22
The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem (2013) 1.22
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Normal and transforming functions of RUNX1: a perspective. J Cell Physiol (2006) 1.15
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol (2006) 1.15
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.13
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol (2005) 1.12
Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials. J Clin Oncol (2013) 1.10
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood (2013) 1.10
The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem (2001) 1.09
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther (2010) 1.05
Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci (2006) 1.04
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood (2011) 1.02
Hemoglobinopathies. Hematology Am Soc Hematol Educ Program (2003) 1.00
Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol (2007) 0.99
Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol (2008) 0.99
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer (2011) 0.99
Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst (2007) 0.98
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res (2008) 0.96
Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother (2011) 0.95
Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res (2014) 0.95
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer (2011) 0.94
Differential expression of caveolin-1 in renal neoplasms. Cancer (2007) 0.93
Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem (2012) 0.93
RUNX1 regulates corepressor interactions of PU.1. Blood (2011) 0.93
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res (2006) 0.92
Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. Surv Ophthalmol (2012) 0.91
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med (2010) 0.91
HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol (2003) 0.91
MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm Res (2011) 0.90
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest (2015) 0.90
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget (2011) 0.90
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget (2012) 0.89
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood (2011) 0.88
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res (2008) 0.88
Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol Carcinog (2007) 0.88
Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol (2009) 0.87
Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys (2013) 0.87
Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother (2012) 0.87
The role and target potential of protein tyrosine phosphatases in cancer. Curr Oncol Rep (2008) 0.86
RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function. J Biol Chem (2007) 0.86
Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci (2012) 0.85
DNA methylation and mechanism of action of 5-azacytidine. Blood (2008) 0.85
Contribution of gastrin-releasing peptide and its receptor to villus development in the murine and human gastrointestinal tract. Mech Dev (2002) 0.84
Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histopathol (2011) 0.84
AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Cancer Res (2004) 0.83
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. Eur J Haematol (2012) 0.83
Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am J Physiol Cell Physiol (2008) 0.83
Circulating tumor cells in uveal melanoma. Future Oncol (2011) 0.83
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs (2010) 0.83
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol (2011) 0.83
Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). Am J Hematol (2014) 0.83
Morphine and breast tumor metastasis: the role of matrix-degrading enzymes. Clin Exp Metastasis (2013) 0.82
S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med (2010) 0.82
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res (2011) 0.82
Renal cell carcinoma: ten years of significant advances. Target Oncol (2010) 0.81